318 related articles for article (PubMed ID: 32600158)
1. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
[TBL] [Abstract][Full Text] [Related]
3. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
Nüesch JP; Lacroix J; Marchini A; Rommelaere J
Clin Cancer Res; 2012 Jul; 18(13):3516-23. PubMed ID: 22566376
[TBL] [Abstract][Full Text] [Related]
6. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
Angelova A; Rommelaere J
Viruses; 2019 May; 11(5):. PubMed ID: 31060205
[TBL] [Abstract][Full Text] [Related]
7. PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis.
Bär S; Rommelaere J; Nüesch JP
PLoS Pathog; 2015 Mar; 11(3):e1004703. PubMed ID: 25742010
[TBL] [Abstract][Full Text] [Related]
8. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
9. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
10. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
11. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review.
Geletneky K; Herrero Y Calle M; Rommelaere J; Schlehofer JR
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):327-30. PubMed ID: 16316394
[TBL] [Abstract][Full Text] [Related]
13. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
14. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
[TBL] [Abstract][Full Text] [Related]
16. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
18. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
Bhat R; Rommelaere J
BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
20. Novel oncolytic viruses: riding high on the next wave?
Stanford MM; Bell JC; Vähä-Koskela MJ
Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
